Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction

• Verfasst von: Clemens, Katri Elina [VerfasserIn]
• Verfasst von: Mikus, Gerd [VerfasserIn]
• Titel: Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction
• Titelzusatz: review of efficacy and safety data in the treatment of patients experiencing chronic pain
• Verf.angabe: Katri Elina Clemens, Gerd Mikus
• Jahr: 2010
• Umfang: 14 S.
• Fussnoten: Published online: 23 December 2009 ; Gesehen am 05.05.2023
• Titel Quelle: Enthalten in: Expert opinion on pharmacotherapy
• Ort Quelle: Abingdon, Oxon : Routledge, Taylor & Francis, 1999
• Jahr Quelle: 2010
• Band/Heft Quelle: 11(2010), 2 vom: Feb., Seite 297-310
• ISSN Quelle: 1744-7666
• DOI: doi:10.1517/14656560903483222
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Administration, Oral
• Sach-SW: Chronic Disease
• Sach-SW: Clinical Trials as Topic
• Sach-SW: Constipation
• Sach-SW: Drug Administration Schedule
• Sach-SW: Drug Therapy, Combination
• Sach-SW: Humans
• Sach-SW: Naloxone
• Sach-SW: Narcotic Antagonists
• Sach-SW: Oxycodone
• Sach-SW: Pain
• Sach-SW: Pain Measurement
• Sach-SW: Quality of Life
• Sach-SW: Receptors, Opioid
• Sach-SW: Safety
• K10plus-PPN: 1844699560

Abstract

IMPORTANCE OF THE FIELD: Despite proven analgesic efficacy, opioid use is associated with frequently dose-limiting bowel dysfunction that seriously impacts patients' quality of life (QoL). Agents used at present to manage opioid-induced constipation do not address the underlying opioid receptor-mediated cause of bowel dysfunction and are often ineffective. There is, therefore, a significant need for more effective treatment options. The combination of the strong opioid oxycodone and the opioid antagonist naloxone has the potential to prevent opioid-induced bowel dysfunction (OIBD) while maintaining analgesic efficacy. - OBJECTIVE: To review the safety and efficacy of oral prolonged-release (PR) oxycodone/naloxone in the treatment of patients experiencing chronic pain. - AREAS COVERED IN THIS REVIEW: A MEDLINE search was done (January 2002 - July 2009) for available literature for prolonged release oxycodone and naloxone in different patient groups. Results were limited to English-language and clinical trials. Data were also obtained from congress materials. WHAT KNOWLEDGE THE READER WILL GAIN: Unmet needs of opioid pain treatment in terms of OIBD, reduced QoL and low treatment compliance, leading to reduced efficacy. A data overview demonstrates the efficacy and tolerability of PR oxycodone/naloxone in the management of severe chronic pain without the burden of severe gastrointestinal adverse events. The combined formulation of a highly effective opioid and an antagonist that acts locally to reduce gastrointestinal side effects is expected to simplify pain management. - TAKE HOME MESSAGE: The combination of PR oxycodone/naloxone offers the potential of maintaining normal bowel function in patients requiring opioid therapy--it is a strong analgesic that is well tolerated.